Corient Private Wealth LP Invests $2.57 Million in Ralliant Corporation $RAL

Key Points

• Institutional interest increased: Corient Private Wealth purchased 34,905 Ralliant shares worth approximately $2.57 million during the second quarter, while several other investment firms also initiated positions.
• Quarterly results exceeded expectations: Ralliant reported earnings of $0.68 per share, beating the $0.63 consensus estimate, on revenue of $567.8 million. The company issued fiscal 2026 EPS guidance of $2.76–$2.90.
• Analyst sentiment is moderately positive: Ralliant has a consensus “Moderate Buy” rating and an average price target of $75.70, although executives recently sold shares under pre-arranged trading plans and the company declared a small quarterly dividend yielding about 0.3%.

Corient Private Wealth LP bought a new stake in Ralliant Corporation (NYSE:RAL - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 34,905 shares of the company's stock, valued at approximately $2,570,000.

Several other hedge funds also recently made changes to their positions in RAL. Cetera Investment Advisers bought a new position in Ralliant in the second quarter worth $700,000. Russell Investments Group Ltd. purchased a new position in Ralliant during the second quarter valued at $1,465,000. EverSource Wealth Advisors LLC bought a new stake in shares of Ralliant during the 2nd quarter valued at $39,000. First Trust Advisors LP bought a new stake in shares of Ralliant during the 2nd quarter valued at $2,013,000. Finally, Federated Hermes Inc. purchased a new stake in shares of Ralliant in the 2nd quarter worth about $326,000.

Ralliant Stock Up 1.0%

RAL opened at $61.61 on Thursday. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.75. The firm has a 50 day moving average price of $67.91 and a 200-day moving average price of $56.92. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The stock has a market capitalization of $6.82 billion, a price-to-earnings ratio of -5.68, a PEG ratio of 2.27 and a beta of 1.54.

Ralliant (NYSE:RAL - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities research analysts forecast that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be given a $0.05 dividend. The ex-dividend date is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Ralliant's dividend payout ratio is presently -1.84%.

Insider Activity

In other news, SVP Karen M. Bick sold 6,062 shares of the firm's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $72.00, for a total value of $436,464.00. Following the transaction, the senior vice president owned 31,668 shares of the company's stock, valued at $2,280,096. This trade represents a 16.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of Ralliant stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $71.79, for a total value of $928,675.44. Following the transaction, the chief executive officer directly owned 251,967 shares in the company, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Oppenheimer boosted their price target on Ralliant from $50.00 to $65.00 and gave the stock an "outperform" rating in a research report on Wednesday, May 13th. Morgan Stanley lifted their price objective on Ralliant from $68.00 to $85.00 and gave the company an "overweight" rating in a research note on Tuesday, June 23rd. Evercore assumed coverage on Ralliant in a report on Tuesday, June 9th. They issued an "outperform" rating and a $80.00 target price on the stock. Weiss Ratings reissued a "sell (d)" rating on shares of Ralliant in a research note on Friday, July 31st. Finally, Wall Street Zen downgraded Ralliant from a "strong-buy" rating to a "buy" rating in a report on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $75.70.

Ralliant Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source